Literature DB >> 22374347

Indirect comparisons of treatment effects in multiple sclerosis.

Maria Pia Sormani, Alessio Signori.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22374347     DOI： 10.1007/s00228-012-1246-1

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN： 0031-6970            Impact factor:   2.953


× No keyword cloud information.
  13 in total

1.  Shall we count the living of the dead.

Authors:  M C SHEPS
Journal:  N Engl J Med       Date:  1958-12-18       Impact factor: 91.245

2.  Treatments for relapsing-remitting multiple sclerosis: summarising current information by network meta-analysis.

Authors:  Fabiola Del Santo; Dario Maratea; Valeria Fadda; Sabrina Trippoli; Andrea Messori
Journal:  Eur J Clin Pharmacol       Date:  2011-11-05       Impact factor: 2.953

3.  European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging--measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group.

Authors:  G Comi; M Filippi; J S Wolinsky
Journal:  Ann Neurol       Date:  2001-03       Impact factor: 10.422

4.  Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial.

Authors:  H Panitch; D S Goodin; G Francis; P Chang; P K Coyle; P O'Connor; E Monaghan; D Li; B Weinshenker
Journal:  Neurology       Date:  2002-11-26       Impact factor: 9.910

5.  Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group.

Authors: 
Journal:  Lancet       Date:  1998-11-07       Impact factor: 79.321

6.  The present efficacy of multiple sclerosis therapeutics: Is the new 66% just the old 33%?

Authors:  Eric C Klawiter; Anne H Cross; Robert T Naismith
Journal:  Neurology       Date:  2009-09-22       Impact factor: 9.910

7.  A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.

Authors:  Ludwig Kappos; Ernst-Wilhelm Radue; Paul O'Connor; Chris Polman; Reinhard Hohlfeld; Peter Calabresi; Krzysztof Selmaj; Catherine Agoropoulou; Malgorzata Leyk; Lixin Zhang-Auberson; Pascale Burtin
Journal:  N Engl J Med       Date:  2010-01-20       Impact factor: 91.245

8.  Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group.

Authors: 
Journal:  Neurology       Date:  1993-04       Impact factor: 9.910

9.  250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study.

Authors:  Paul O'Connor; Massimo Filippi; Barry Arnason; Giancarlo Comi; Stuart Cook; Douglas Goodin; Hans-Peter Hartung; Douglas Jeffery; Ludwig Kappos; Francis Boateng; Vitali Filippov; Maria Groth; Volker Knappertz; Christian Kraus; Rupert Sandbrink; Christoph Pohl; Timon Bogumil; P O'Connor; M Filippi; B Arnason; S Cook; D Goodin; H-P Hartung; H-P Harung; L Kappos; D Jeffery; G Comi
Journal:  Lancet Neurol       Date:  2009-09-02       Impact factor: 44.182

10.  A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis.

Authors:  Chris H Polman; Paul W O'Connor; Eva Havrdova; Michael Hutchinson; Ludwig Kappos; David H Miller; J Theodore Phillips; Fred D Lublin; Gavin Giovannoni; Andrzej Wajgt; Martin Toal; Frances Lynn; Michael A Panzara; Alfred W Sandrock
Journal:  N Engl J Med       Date:  2006-03-02       Impact factor: 91.245
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.